Sudeep Pharma reported a 29.8% year-on-year increase in consolidated net profit for the first quarter of FY26, reaching ₹405.87 lakh. The Vadodara-based pharmaceutical company saw its total income from operations rise 26% to ₹1,637.16 lakh, driven by robust demand across its product portfolio. Standalone results mirrored this growth trajectory, with net profit climbing 34% to ₹338.29 lakh against a revenue backdrop of ₹1,154.84 lakh.

The Board of Directors approved the unaudited financial results at its meeting held on August 4, 2026. The results were reviewed by the Audit Committee and filed with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chairman and Managing Director Sujit Jaysukh Bhayani signed off on the financial statement, which is also available on the company’s website.

Financial Performance

The company’s consolidated earnings per share (EPS) stood at ₹3.59 for the quarter ended June 30, 2026, up from ₹2.84 in the corresponding period last year. Diluted EPS remained unchanged at ₹3.59. For the full fiscal year FY26, basic EPS was ₹15.50.

Standalone revenue from operations increased to ₹1,154.84 lakh from ₹867.94 lakh in Q1FY25. The standalone profit before tax rose to ₹454.08 lakh from ₹338.27 lakh, reflecting improved operational efficiency and cost management during the period.

What the Numbers Show

The divergence between standalone and consolidated profit growth highlights the contribution of subsidiaries or associates to the bottom line. While standalone profit grew by 34%, consolidated profit grew by 30%, suggesting that while core operations are expanding rapidly, associated entities may have faced margin pressures or lower growth rates compared to the previous quarter. The consistent rise in both top-line and bottom-line figures indicates sustained market demand for Sudeep Pharma’s offerings without significant one-time gains driving the result.

Sudeep Pharma Limited reported a 30% year-on-year increase in consolidated net profit to ₹40.6 crore for the quarter ended June 30, 2026 (Q1FY27), driven by a 27% surge in revenue from operations to ₹158.3 crore. This performance, achieved despite geopolitical uncertainties, intermittent gas supply constraints, and elevated logistics costs, underscores resilient operational efficiency with an EBITDA margin of 34.69%. Strategically, the company is accelerating its pivot into energy storage, marking significant progress on its ₹300 crore battery materials plant in Dahej, Gujarat, while integrating Nutrition Supplies & Services (NSS) to broaden its global footprint in vitamin and mineral blends.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 4, 2026, in compliance with Regulation 30(6) of the SEBI Listing Regulations, 2015. Statutory auditor B S R and Co conducted a limited review pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The review covered financial statements prepared under Indian Accounting Standard 34 (Ind AS 34). Notably, the Board was strengthened with the appointment of Milin Mehta as an Independent Director, bringing expertise in strategy and corporate governance.

Financial Performance

Consolidated total income reached ₹163.7 crore, up from ₹130.1 crore in Q1FY26. Other income stood at ₹5.4 crore. Total expenses were ₹109.4 crore, comprising cost of materials consumed at ₹56.6 crore and employee benefits expense at ₹14.3 crore. Profit before tax rose to ₹54.3 crore from ₹44.1 crore in the prior year period. The following table summarises the key consolidated financial metrics for the quarter:

Standalone net profit increased to ₹33.8 crore from ₹25.2 crore. Standalone revenue from operations grew to ₹105.7 crore. Earnings per share (basic) were ₹3.59 on a consolidated basis and ₹3.00 on a standalone basis.

Segment Analysis and Strategic Initiatives

The pharmaceutical, food, and nutrition segment generated external revenues of ₹108.4 crore, up significantly from ₹83.0 crore in Q1FY26, with a segment result before other income, finance costs, and tax of ₹41.9 crore. The speciality ingredients segment reported external revenues of ₹49.9 crore, up from ₹41.9 crore, yielding a segment result of ₹13.1 crore. The Specialty Ingredients business benefited from robust growth in Premix and Encapsulation portfolios, while NSS integration progressed as planned despite subdued demand in certain European customer segments due to elevated energy costs.

Sudeep Advanced Materials (SAM) continues strong progress toward Phase 1 commissioning by March 2027. Customer engagement has expanded with two additional strategic MoUs signed with leading South Korean cathode active material (CAM) manufacturers during the quarter. Planning activities for Phase 2 are already underway.

Capacity Expansion and Battery Materials

The ₹300 crore Battery Materials Plant in Dahej, Gujarat, aims to produce Battery Grade Iron Phosphate for EV and Energy Storage applications on an 80,980 sq. mt. land area. Financing will be through internal accruals and debt. Sudeep Pharma positions itself as a premier non-Chinese supplier for battery-grade iron phosphate PCAM, leveraging FEOC-compliant supply chains aligned with US IRA and EU Critical Raw Materials Act regulations.

The following table outlines the key parameters of the battery materials expansion:

Total capacity visibility is projected to rise from 65,000 MT in FY25 to 1,48,700 MT in FY27. This includes a greenfield addition of 51,200 MT in pharma, food, and nutrition, and 25,000 MT in battery materials. Existing pharma iron phosphate capacity has been enhanced to produce 5,000 MT of battery-grade material.

What the Numbers Show

The divergence between revenue growth (27%) and expense growth (27.2%) indicates stable operating leverage, while the slight dip in EBITDA margin from 35.12% to 34.69% reflects minor pressure from higher material or logistics costs. The pharmaceutical, food, and nutrition segment remains the primary profit driver, contributing approximately 82% of the total segment result before tax. The successful integration of NSS and the strategic pivot into battery materials highlight a dual-growth strategy: consolidating market leadership in excipients while capturing high-value opportunities in the energy storage sector.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0QPI01025/36ae1296-7130-479b-be6c-764d62833ae5.pdf